AstraZeneca (NYSE: AZN) board member Rene Haas to step down

Rhea-AI Filing Summary

AstraZeneca PLC announced a change to its Board of Directors. Rene Haas will step down as a Non-Executive Director on 30 April 2026 as he assumes an additional role as Chief Executive Officer of SoftBank Group International alongside his position as CEO of Arm Holdings plc.

The company stated that, under section 430(2B) of the Companies Act 2006, Haas will receive only his non-executive director fees for his time on the Board and no payment for loss of office.

Key Figures

Board departure date: 30 April 2026 Companies Act reference: section 430(2B) Countries where medicines are sold: more than 125 countries

3 metrics

Board departure date 30 April 2026 Effective date Rene Haas steps down as Non-Executive Director

Companies Act reference section 430(2B) Governs disclosure of payments for loss of office

Countries where medicines are sold more than 125 countries Global reach of AstraZeneca’s prescription medicines

Key Terms

Non-Executive Director, Companies Act 2006, payment for loss of office, biopharmaceutical company, +1 more

5 terms

Non-Executive Director financial

"He will step down as a Non-Executive Director of AstraZeneca PLC on 30 April 2026"

A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.

Companies Act 2006 regulatory

"For the purposes of section 430(2B) of the Companies Act 2006, other than non-executive director fees"

payment for loss of office financial

"Rene will not receive any remuneration or payment for loss of office"

biopharmaceutical company financial

"AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines"

Oncology medical

"prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

Form 6-K: How Foreign Companies Report to the SEC →

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of April 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Directorate change

23 April 2026

Change to AstraZeneca Board of Directors

AstraZeneca congratulates Rene Haas on his appointment as Chief Executive Officer of SoftBank Group International, in addition to his position as Chief Executive Officer of Arm Holdings plc. Taking into account this additional workload, we have mutually agreed that Rene will not have enough time available to fully assume his AstraZeneca Board member duties. He will step down as a Non-Executive Director of AstraZeneca PLC on 30 April 2026, as he takes up his new appointment.

Michel Demaré, Chair of AstraZeneca, said "On behalf of the whole Board, I would like to thank Rene for his contributions drawing on his considerable business acumen and extensive experience of data science, computing and AI. We wish him all the best for his future endeavours."

For the purposes of section 430(2B) of the Companies Act 2006, other than non-executive director fees for his time on the Board, Rene will not receive any remuneration or payment for loss of office.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 23 April 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What board change did AstraZeneca (AZN) report in this Form 6-K?

AstraZeneca reported that Rene Haas will step down as a Non-Executive Director on 30 April 2026. The change follows his appointment as Chief Executive Officer of SoftBank Group International, in addition to his existing CEO role at Arm Holdings plc.

When will Rene Haas leave AstraZeneca’s (AZN) Board of Directors?

Rene Haas will leave AstraZeneca’s Board on 30 April 2026. His departure coincides with taking up the role of Chief Executive Officer of SoftBank Group International while continuing as Chief Executive Officer of Arm Holdings plc, increasing his external workload.

Why is Rene Haas stepping down from the AstraZeneca (AZN) board?

Rene Haas is stepping down because his new responsibilities as Chief Executive Officer of SoftBank Group International, combined with his role as CEO of Arm Holdings plc, mean he will not have enough time to fully perform his AstraZeneca Board duties.

Will Rene Haas receive any payment for loss of office from AstraZeneca (AZN)?

No, Rene Haas will not receive any payment for loss of office from AstraZeneca. Under section 430(2B) of the Companies Act 2006, he will receive only non-executive director fees for his time served on the Board, with no additional remuneration.

What type of company is AstraZeneca (AZN)?

AstraZeneca is a global, science-led biopharmaceutical company focused on prescription medicines. Its main areas are Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries worldwide.